--- title: "輝瑞第一季度收入增長，但由於研發支出增加，利潤下降" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285199732.md" description: "輝瑞報告第一季度收入增長 5%，達到 144.5 億美元，超出華爾街預期。然而，淨收入下降至 26.9 億美元，受到研發費用上漲 12% 的影響。調整後的每股收益為 75 美分，超過分析師預測的 72 美分。公司仍面臨 COVID-19 產品銷售下滑的挑戰，並專注於新藥開發，包括收購 Metsera。輝瑞維持全年收入指引在 595 億美元至 625 億美元之間，調整後每股收益在 2.80 美元至 3 美元之間" datetime: "2026-05-05T11:45:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285199732.md) - [en](https://longbridge.com/en/news/285199732.md) - [zh-HK](https://longbridge.com/zh-HK/news/285199732.md) --- # 輝瑞第一季度收入增長，但由於研發支出增加，利潤下降 By Nicholas G. Miller Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending. The company posted net income of $2.69 billion, or 47 cents a share, compared with $2.97 billion, or 52 cents a share, the year prior. Adjusted earnings were 75 cents a share. Analysts polled by FactSet expected 72 cents a share. The company said its research and development expenses rose 12% due to higher spending in certain oncology and obesity product candidates. Cost of sales also increased on the unfavorable impact of foreign exchange and the favorable revision of the company's estimate of accrued royalties in the first quarter of 2025. Revenue rose 5% to $14.45 billion. Wall Street expected $13.84 billion. The gains were driven by growth for its Padcev cancer drug, its Eliquis blood thinner, Oncology biosimilars and its Nurtec migraine treatment and were partially offset by declines in COVID-19 product revenues. Demand for Pfizer's Covid-19 pharmaceuticals has fallen precipitously since the peak of the pandemic and the company has been looking for new drugs to make up for the drop-off in sales. As part of its strategy to beef up its pipeline, Pfizer agreed to acquire weight-loss drug startup Metsera last year in a deal that could be worth more than $10 billion. The company reiterated its full-year guidance for revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Analysts see full-year sales of $61.38 billion and adjusted earnings of $2.96 a share. Write to Nicholas G. Miller at nicholas.miller@wsj.com. (END) Dow Jones Newswires May 05, 2026 07:31 ET (11:31 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [PFE.US](https://longbridge.com/zh-HK/quote/PFE.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [TBXU.US](https://longbridge.com/zh-HK/quote/TBXU.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [FDS.US](https://longbridge.com/zh-HK/quote/FDS.US.md) - [MTSR.US](https://longbridge.com/zh-HK/quote/MTSR.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [輝瑞在第二階段取得強勁的積極結果後，推進關鍵的兒童肺炎球菌疫苗項目 | PFE 股票新聞](https://longbridge.com/zh-HK/news/287035698.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md) - [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md) - [華爾街看好健康保險板塊，分析師上調多家公司評級](https://longbridge.com/zh-HK/news/287081375.md)